What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

1 day ago · Sarepta Therapeutics SRPT has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below …

$128.79
OFF

A Closer Look At 14 Analyst Recommendations For Sarepta …

2 weeks from now

Jan 10, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $128.79, a high estimate of $224.00, and a low estimate of $40.00. …

businessinsider.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics …

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

sahmcapital.com

$175.72
OFF

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Analyst Ratings, Price ...

2 weeks from now

Sarepta Therapeutics Inc has a consensus price target of $175.72 based on the ratings of 25 analysts. The high is $230 issued by Leerink Partners on June 24, 2024.

benzinga.com

$170.69
OFF

Sarepta Therapeutics (SRPT) Stock Forecast: Analyst Ratings ...

2 weeks from now

35 analysts have given Sarepta Therapeutics (SRPT) a consensus rating of Buy while the Sarepta Therapeutics (SRPT) price prediction in 2025 is $170.69

public.com

$174
OFF

What 25 Analyst Ratings Have To Say About Sarepta Therapeutics

2 weeks from now

Jun 23, 2023 · These 25 analysts have an average price target of $174.6 versus the current price of Sarepta Therapeutics at $115.9999, implying upside. Below is a summary of how these 25 …

businessinsider.com

$164.08
OFF

12 Analysts Have This To Say About Sarepta Therapeutics

2 weeks from now

May 20, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00. This …

businessinsider.com

$182.00
OFF

Sarepta Therapeutics Stock Supported By LGMD Pipeline Progress, …

2 weeks from now

2 days ago · On Tuesday, Piper Sandler reaffirmed its Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) stock, maintaining a price target of $182.00. The endorsement follows …

investing.com

$75.00
OFF

Temporary Revenue Surge And Market Penetration ... - Markets …

2 weeks from now

1 day ago · Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price target at $75.00. Discover …

businessinsider.com

112%
OFF

Sarepta Maintained At Sell By H.C. Wainwright On 112% Q/Q Growth

2 weeks from now

1 day ago · On Wednesday, H.C. Wainwright analysts reiterated a Sell rating on Sarepta Therapeutics stock (NASDAQ: SRPT). The firm's analysis follows Sarepta's recent pre …

investing.com

$164.08
OFF

12 Analysts Have This To Say About Sarepta Therapeutics - Nasdaq

2 weeks from now

May 20, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.

nasdaq.com

FAQs about What 14 Analyst Ratings Have To Say About Sarepta Therapeutics Coupon?

What do analyst ratings mean for Sarepta Therapeutics?

These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for Sarepta Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations. ...

How can I view Sarepta Therapeutics's market performance?

To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table. Stay up to date on Sarepta Therapeutics analyst ratings. ...

Does Sarepta Therapeutics have a good return on equity?

Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.44%, the company may face hurdles in generating optimal returns for shareholders. ...

Why do analysts'maintain' or 'raise' their stance on Sarepta Therapeutics?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. ...

What factors affect Sarepta Therapeutics' market capitalization?

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity. Revenue Growth: Sarepta Therapeutics displayed positive results in 3 months. ...